AU Patent

AU2024368633A1 — Glp1-r/gipr dual peptide agonists and use thereof

Assigned to Beta Pharma Inc · Expires 2026-04-02 · 0y expired

What this patent protects

Provided is dual target agonist peptides, and more specifically to a series of dual target agonists that can simultaneously activate the human Glucagon like peptide-1 (GLP-1) receptor and the human glucose dependent insulinotropic polypeptide (GIP) receptor, as well as its pharma…

USPTO Abstract

Provided is dual target agonist peptides, and more specifically to a series of dual target agonists that can simultaneously activate the human Glucagon like peptide-1 (GLP-1) receptor and the human glucose dependent insulinotropic polypeptide (GIP) receptor, as well as its pharmaceutical salts and pharmaceutical compositions. The peptides have dual agonist effect and can be used for the treatment of diabetes, obesity and other related diseases.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024368633A1
Jurisdiction
AU
Classification
—
Expires
2026-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Beta Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.